Search results | companion diagnostics

Reports

Companion Diagnostics Partnering Terms and Agreements

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Cancer Diagnostics Partnering Terms and Agreements

The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in cancer diagnostics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer diagnostics partnering contract documents Top cancer diagnostics deals by value   The more »

Personalized Medicine Partnering Terms & Agreements

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Companion diagnostics

Companion diagnostics are assays that measure levels of proteins, genes or specific mutations….

Companion diagnostics: recent life science industry trends

Companion diagnostics is an increasingly active component of healthcare business and life science deals development suggests industry trends

Molecular diagnostics partnering: recent life science trends 2009-2014

Molecular diagnostics is the use of molecular biology for medical testing and clinical applications. This discipline determines how genes and proteins interact in a cell. This partnering article reflects on the recent life science trends in the molecular diagnostics technology arena.

Diagnostics partnering: recent life science trends 2009-2014

Diagnostics are subject to numerous partnering deals every year. Here we provide a review of recent life science trends in deal making activity

Diagnostics

Diagnostics are any kind of medical test performed to aid in the diagnosis or detection of disease.

Bio news: Diagnostics creating ‘niche buster’ drugs

When US regulators this month authorised a genetic test that determines  whether or not patients will benefit from a cancer drug, they heralded an  important acceleration in “personalised medicine” that could turn the  pharmaceutical industry’s business model on its head

Xenon collaborates with Genentech for discovery of targeted pain therapeutics and diagnostics

Genentech and Xenon will collaborate in the development of novel targeted pain therapeutics as well in the development of associated companion diagnostics

Eyeing diagnostics, Roche up for $3 billion deal

Roche Holding AG (ROG) is open to a deal as big as $3 billion and the Swiss drugmaker is ready to “seize” the right opportunities for acquisitions, Chief Executive Officer Severin Schwan said.

Diagnostic imaging partnering : recent life science trends 2009-2014

Recent life science trends has seen tremendous developments in new diagnostic and medical imaging techniques. Imaging tools such as CT scans, endoscopes, PET, SPECT, ultrasound and MRI are all showing promise and precise accuracy in diagnosing diseases like cancer, hospital care, cardiovascular, etc

Personalized medicine

Personalized medicine proposes customization of healthcare – with medical decisions, practices, and/or…

Events

Sorry, your search returned no results.


Deals

Qiagen and Astellas form a biotech partnership to develop companion diagnostics

QIAGEN announced a biotech partnership agreement with Astellas Pharma to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases.

Ventana and Bayer ink pharma alliance for development of companion diagnostics

Ventana Medical Systems has entered into a multi-year pharma alliance with Bayer Pharma to develop companion diagnostics, with a focus on immunohistochemistry (IHC), across Bayer’s portfolio of targeted therapy projects.

AstraZeneca big pharma deals Myriad Genetics for companion diagnostics supply

Myriad Genetics has entered into expanded, non-exclusive global pharma deals with AstraZeneca to provide companion diagnostics for the olaparib Phase 3 clinical development program.

Merck Serono pharma partners Life Technologies for companion diagnostics collaboration

Life Technologies Corporation signed agreement to collaborate with pharma partners Merck Serono for current and future companion diagnostic projects.

Eli Lilly in companion diagnostics agreement with Qiagen

QIAGEN has entered into a master collaboration agreement with Eli Lilly, the top pharmaceutical company,and Company for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas.

Dako in collaboration with big pharma Pfizer for companion diagnostics

Dako has entered into a collaboration agreement with Pfizer, the big pharma company headquartered in New York, USA,  in the field of companion diagnostics.

Bayer & Qiagen in companion diagnostics pharma partnering

QIAGEN  and Bayer HealthCare announced a pharma partnering collaboration agreement for the development and commercialization of companion diagnostics

Life Technologies signs agreement with GSK Biologicals, seeking expanded use of platform technologies into companion diagnostics

Agreement with GlaxoSmithKline Biologicals to develop a diagnostic to be used as a companion test with a GSK candidate cancer immunotherapy.

AstraZeneca and Dako in agreement to develop companion diagnostics for cancer treatments

Under the agreement, the companies will work together to develop diagnostic tests to help physicians determine the most appropriate cancer treatment for patients. The financial terms of the deal were not disclosed.

Aveo and Biodesix sign a pharma alliance for companion diagnostic test

AVEO Oncology and Biodesix entered into a worldwide pharma alliance to develop and commercialize AVEO’s hepatocyte growth factor inhibitory antibody ficlatuzumab, with a Biodesix companion diagnostic test.